Sensei Biotherapeutics (SNSE) Set to Announce Quarterly Earnings on Monday

Sensei Biotherapeutics (NASDAQ:SNSE – Get Rating) is scheduled to announce its earnings results on Monday, March 20th.

Sensei Biotherapeutics Trading Up 2.2 %

SNSE stock opened at $1.42 on Friday. The company has a market cap of $43.62 million, a P/E ratio of -0.97 and a beta of -0.21. Sensei Biotherapeutics has a twelve month low of $1.30 and a twelve month high of $2.86. The company has a quick ratio of 13.95, a current ratio of 13.95 and a debt-to-equity ratio of 0.01. The business has a fifty day moving average of $1.50 and a 200-day moving average of $1.54.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SNSE. Jane Street Group LLC bought a new stake in Sensei Biotherapeutics in the first quarter valued at approximately $25,000. Raymond James & Associates bought a new position in shares of Sensei Biotherapeutics during the first quarter worth approximately $30,000. Virtu Financial LLC bought a new position in Sensei Biotherapeutics during the 4th quarter worth $39,000. Western Standard LLC bought a new position in Sensei Biotherapeutics during the 4th quarter worth $69,000. Finally, Bank of America Corp DE increased its stake in Sensei Biotherapeutics by 91.7% during the 1st quarter. Bank of America Corp DE now owns 48,001 shares of the company’s stock worth $110,000 after acquiring an additional 22,967 shares during the period. 20.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Citigroup initiated coverage on Sensei Biotherapeutics in a research note on Tuesday, December 13th. They issued a “buy” rating for the company.

Sensei Biotherapeutics Company Profile

(Get Rating)

Sensei Biotherapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways.